Patient preferences for reducing bowel adverse events following prostate radiotherapy

被引:3
|
作者
Mishra, Mark, V [1 ]
Thayer, Winter Maxwell [2 ,3 ]
Janssen, Ellen [4 ]
Hoppe, Bradford [5 ]
Eggleston, Caitlin [1 ]
Bridges, John F. P. [6 ]
机构
[1] Univ Maryland, Sch Med, Dept Radiat Oncol, Baltimore, MD 21201 USA
[2] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA
[3] Johns Hopkins Univ, Sch Nursing, Baltimore, MD USA
[4] Ctr Med Technol Policy, Baltimore, MD USA
[5] Mayo Clin Florida, Dept Radiat Oncol, Tampa, FL USA
[6] Ohio State Univ, Dept Biomed Informat, Columbus, OH 43210 USA
来源
PLOS ONE | 2020年 / 15卷 / 07期
关键词
DISCRETE-CHOICE EXPERIMENTS; LINEAR SCORING RULES; CONJOINT-ANALYSIS; REPORTED OUTCOMES; PROTON THERAPY; CANCER; WEIGHTS;
D O I
10.1371/journal.pone.0235616
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background The Extended Prostate Cancer Index Composite (EPIC) instrument is a commonly used patient reported outcome (PRO) tool in prostate cancer clinical trials. Summary scores for EPIC subscales are calculated by averaging patient scores for attributes (e.g., side effects), implying equal weighting of the attributes in the absence of evidence showing otherwise. Methods We estimated patient preferences for each of the attributes included in the bowel subscale of the EPIC instrument using best-worst (B-W) scaling among a cohort of men with prostate cancer. Patients were presented with multiple tasks in which they were asked to indicate which attribute they would find most and least bothersome at different levels of severity. Analysis utilized both (simple) B-W counts and scores to estimate patient preferences for each attribute as well as attribute levels. Results A total of 174 respondents from two institutions participated in the survey. Preference estimates for each of the five attributes included in the EPIC-26 bowel subscale showed wide variation preferences: 'losing control of bowel movements' was found to be the most bothersome attribute, with a B-W score of -0.48, followed by bowel urgency which also had negative B-W score (-0.04). Increased frequency of bowel movements was the least bothersome attribute, with a B-W score of +0.33, followed by bloody stools (+0.12), and pelvic/rectal pain (+0.06). Analysis of preference weights for attribute bother levels showed preference estimates be linear. Conclusions We provide novel evidence on patient preferences for side effect reduction following prostate radiotherapy. Within the bowel sub-scale of the EPIC-26 short form, we found that bowel incontinence was perceived to be the most bothersome treatment effect, while increased bowel frequency was least bothersome to patients.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Patient Preferences for Faster Home-Based Subcutaneous Immunoglobulin Infusion Therapy and the Effect on Adverse Events
    Rutland, Brent
    Southworth, Carleton
    Bosshard, Jasmin
    PATIENT PREFERENCE AND ADHERENCE, 2025, 19 : 615 - 621
  • [42] Aspects on reducing gastrointestinal adverse effects associated with radiotherapy
    Henriksson, Roger
    Bergstrom, Per
    Franzen, Lars
    Lewin, Freddi
    Wagenius, Gunnar
    Acta Oncologica, 38 (02): : 159 - 164
  • [43] Aspects on reducing gastrointestinal adverse effects associated with radiotherapy
    Henriksson, R
    Bergström, P
    Franzén, L
    Lewin, F
    Wagenius, G
    ACTA ONCOLOGICA, 1999, 38 (02) : 159 - 164
  • [44] Multi-institutional search for patient factors associated with adverse events following tracheotomy
    Montalbaron, Michael B.
    Tian, Likun
    Yu, Victoria X.
    Awad, Mahmoud I.
    Bensoussan, Yael
    Leber, W. Schaefer
    Lamm, Scott
    Edelmayer, Luke
    Postma, Gregory N.
    Bock, Jonathan M.
    Anderson, Jennifer
    Pitman, Michael J.
    AMERICAN JOURNAL OF OTOLARYNGOLOGY, 2023, 44 (02)
  • [45] Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer
    Hershman, Dawn L.
    Unger, Joseph M.
    Wright, Jason D.
    Ramsey, Scott
    Till, Cathee
    Tangen, Catherine M.
    Barlow, William E.
    Blanke, Charles
    Thompson, Ian M.
    Hussain, Maha
    JAMA ONCOLOGY, 2016, 2 (04) : 453 - 461
  • [46] Patient safety and adverse events in pathology
    Engel, Ulla
    Moller-Hansen, Kirsten
    Hellebek, Annemarie
    Rygaard, Carsten
    APMIS, 2008, 116 (03) : 233 - 233
  • [47] PATIENT-REPORTED ADVERSE EVENTS
    Nakajima, T.
    ANNALS OF ONCOLOGY, 2012, 23 : 75 - 75
  • [48] Testosterone Treatment and the Risk of Prostate Adverse Events
    Levy, Jason A.
    Burnett, Arthur L.
    Dobs, Adrian S.
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2022, 51 (01) : 123 - 131
  • [49] Patient Demographics and Major Adverse Cardiovascular Events after Androgen Deprivation Therapy for Prostate Cancer
    Wallis, Christopher J. D.
    Chen, Kevin C.
    Atkinson, Stuart
    Boldt-Houle, Deborah M.
    ADVANCES IN UROLOGY, 2024, 2024
  • [50] Management of Enzalutamide Related Adverse Events for Castration Resistant Prostate Cancer by Patient Reported Outcomes
    Iguchi, Taro
    Yasuda, Sayaka
    Kato, Minoru
    Yamazaki, Takeshi
    Tamada, Satoshi
    Nakatani, Tatsuya
    ANNALS OF ONCOLOGY, 2016, 27